NCT02952339View on ClinicalTrials.gov

Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV LID ΔM2-2 1030s vaccine

10\^5.0 PFU; administered as nose drops

BIOLOGICAL

Placebo

Administered as nose drops

Trial Locations (2)

20708

Center for Immunization Research South, Laurel

21205

Center for Immunization Research, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02952339 - Evaluating the Infectivity, Safety, and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine in RSV-Seronegative Infants and Children 6 to 24 Months of Age | Biotech Hunter | Biotech Hunter